Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients

Journal of Clinical Laboratory Analysis

Volumn 15, Issue 3, 2001, Pages 127-130

  Quiros Roldan, E ^a,b   Moretti, F ^a   Airoldi, M ^a   Fausti, C ^a   Chiodera, A ^a   Castelli, F ^a   Carosi, G ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Institute of Infectious and Tropical Diseases   (Italy)

Author keywords

Genotyping; HIV multiexperienced

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE; SERINE;

ARTICLE; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PREVALENCE; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CODON; DRUG RESISTANCE, MULTIPLE; GENOTYPE; HIV-1; HUMANS; ITALY; MUTATION; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035020615     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.1015     Document Type: Article

References (22)

1. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
2. Predictors of optimal virologic response to potent antiretroviral therapy
3. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
4. The use of plasma HIV-RNA as a study endpoint in efficacy trials of antiretroviral drugs
5. Limits of resistance testing
6. Genotypic resistance analysis of plasma HIV-1 RNA in patients failing to the maintenance phase in Trilege trial
7. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
8. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
9. Final results of CPCRA046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
10. Emergence of HIV-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
11. Altered drug sensitivity, fitness and evolution of HIV-1 with pol gene mutations confering multidideoxynucleoside resistance
12. Emergence of multidideoxynucleoside-resistant HIV-1 variants. Viral sequence variation and disease progression in patients receiving antiretroviral chemotherapy
13. The reverse Transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy
14. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up
15. HIV drug susceptibility drug AZT monotherapy compared with AZT plus 2′3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. The Protocol 34.225-202 Collaborative Group
16. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
17. Emergence of multidideoxynucleoside-resistant HIV-1 variants. Viral sequence variation and disease progression in patients receiving antiretroviral chemotherapy
18. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and retroviral-experienced HIV-infected patients in Spain
19. Prevalence and characteristics of multinucleoside-resistant HIV-1 among european patients receiving combinations of nucleoside analogues
20. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
21. Prevalence of renotypic resistance to nucleoside analogues and protease inhibitors in Spain
22. Antiretroviral drug resistance testing in adults with HIV infection. Consensus statement